Intellia Therapeutics Investor Presentation — May 2019

Document content

May 2, 20192Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”) within themeaning ofthePrivate Securities Litigation Reform

Actof1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s ability toadvance andexpand

theCRISPR/Cas 9technology todevelop human therapeutic products, aswellasourCRISPR/Cas 9intellectual property portfolio ;ourability toachieve stable

oreffective genome editing ;ourability toeffectively administer onedose ormultiple doses ofourCRISPR/Cas 9product candidates ;thepotential timing and

advancement ofourpreclinical studies, including continuing non-human primate studies forourTransthyretin Amyloidosis (“ATTR”) program andother studies

forourother programs (such as,alpha -1antitrypsin deficiency (“AATD”)), and human clinical trials ;thetiming andpotential achievement ofmilestones to

advance ourpipeline including initiation ofinvestigational new drug (“IND”) -enabling studies and filing INDs ;ourability toreplicate results achieved inour

preclinical studies, including those inourATTR, AATD, primary hyperoxaluria type 1(“PH1”)andWilms’ Tumor 1(“WT 1")/acute myeloid leukemia programs,

aswellascentral nervous system -related efforts, inanyfuture studies, including human clinical trials ;ourability togenerate data andreplicate results relating

toenhancements toourproprietary lipidnanoparticle (“LNP”) technology, including itsformulation andcomponents, inpreclinical orclinical studies, orthatany

enhancements willresult inanimproved product candidate profile ;thepotential development ofourproprietary LNP-adeno -associated virus (“AAV”) hybrid

delivery system toadvance ourcomplex genome editing capabilities ;thepotential development ofother invivo orexvivo celltherapeutics ofalltypes, and

those targeting WT1inparticular, using CRISPR/Cas 9technology ;ourability toconduct successful IND-enabling studies ofalead ATTR development

candidate andsubsequently submitting anINDapplication thatwillbeaccepted bytheregulatory agencies ;ourintent togenerate andpresent additional data

fororgans beyond theliver, additional insertion/repair data, andpreclinical data insupport ofourfirstexvivo programs onimmuno -oncology during 2019 or

thereafter ;theintellectual property position and strategy ofIntellia’s licensors orother parties from which itderives rights, aswell asthird-parties and

competitors ;actions bygovernment agencies ;ourgrowth asacompany andtheanticipated contribution ofthemembers ofourboard ofdirectors andour

executives toouroperations andprogress ;theimpact ofourcollaborations onourresearch anddevelopment programs ;thepotential timing ofregulatory